ObjectiveThe objective of this research was to analyze the prognostic significance of the minimum count of lymphocytes (LY) and the corresponding ratio of neutrophil‐to‐lymphocyte (NLR) in cervical cancer (CC) patients receiving radiotherapy.MethodsWe retrospectively collected data from 202 CC patients who received concurrent chemoradiotherapy or radiotherapy alone at our hospital. Statistical methods including the Kaplan–Meier method, log‐rank test and the Cox proportional hazards model were included to examine survival differences and identify independent factors that may affect overall survival (OS) and progression‐free survival (PFS).ResultsThe research enrolled a total of 202 patients. Patients with higher LY levels and lower NLR values during radiotherapy had significantly better survival prognosis than those with lower LY levels and higher NLR values. Multivariate COX regression analysis revealed that FIGO stage I, pathological types of SqCC, absence of lymph node metastasis, concurrent chemoradiotherapy, higher LY levels during radiotherapy, and lower NLR values before radiotherapy were independently associated with poorer PFS. Similarly, FIGO stage I, absence of lymph node metastasis and lower NLR values during and before radiotherapy were independently linked with poorer OS.ConclusionMinimum LY value and its corresponding NLR during radiotherapy serve as prognostic factors for CC.

This study aimed to evaluate the correlation between the pre-treatment peripheral platelet-to-lymphocyte ratio (PLR) and the prognostic nutritional index (PNI) with the efficacy and prognosis of radiotherapy for cervical cancer. A total of 110 patients with cervical cancer who received radiotherapy at our hospital from November 2017 to November 2020 were retrospectively analysed. The cut-off values of PLR and PNI were obtained using the receive operating characteristic curve (ROC) and the Youden index. The patients were divided into high PLR and low PLR and high PNI and low PNI groups. We compared the clinical characteristics, 3-year overall survival (OS), and progression-free survival (PFS) between the high and low PLR groups, as well as the high and low PNI groups of patients. Cox regression was used to analyse the factors influencing OS and PFS. The median follow-up duration was 26 months. The optimal cut-off value for PLR was 186.88 and that for PNI was 47.35. The 3-year OS values were 81.00% and 97.10% for the high PLR (PLR > 186.88) and low PLR (PLR ≤ 186.88) groups, respectively, and the 3-year PFS values were 59.50% and 88.20% for the high PLR and low PLR groups, respectively, with statistically significant differences (p < 0.05). The 3-year OS values were 97.50% and 74.20% for the high PNI (PNI > 47.35) and the low PNI (PNI ≤ 47.35) groups, respectively, and the 3-year PFS values were 87.30% and 51.60% for the high PNI and low PNI groups, respectively, with statistically significant differences (p < 0.05). Multifactorial Cox regression analyses revealed that high PLR value (PLR > 187.88), low PNI value (PNI ≤ 47.35), histological type, and FIGO stage were independent risk factors for the OS of cervical cancer. Pretreatment PNI values and PLR values can be used as simple and feasible predictors of clinical efficacy and prognosis for patients treated with radiotherapy for cervical cancer.

Background Cervical cancer (CC) still represents an important challenge for female malignant tumors. In recent years, increasing evidence has indicated that EPHB2 plays a significant part in the origin and progression of many types of cancer in humans. Nevertheless, the mechanism of EPHB2 in CC remains inexplicable. The purpose of this study is to determine the prognostic value and related regulatory mechanism of EPHB2 in CC. Methods The basic clinical information and transcriptome data related to CC patients were downloaded from TCGA database and conducted standardization processing. TIMER2.0 was used for analyzing the EPHB2 expression differences of between 38 cancer types and corresponding normal tissues. The expression and prognostic value (including OS and RFS) of EPHB2 in different cancer types were determined by GEPIA2. And the starbase database was used for exploring the upstream miRNAs and lncRNAs of EPHB2. Then, The correlation analysis of EPHB2, miRNA and lncRNA and the exploration of prognostic value and expression of miRNAs in CESC was conducted using the R language packages. We also analyzed the prognostic value and expression difference of 187 lncRNAs based on the UALCAN database. Finally, we performed the correlation analysis between EPHB2 and multiple immune cells using the R language package. Results In our study, the AC073957.3/hsa-miR-150-5p axis was found to be the most potential upstream ncRNA-related regulator of EPHB2 in CC. And the results of immune correlation infiltration analysis suggest that as EPHB2 copy numbers fluctuate in CESC there is an obvious difference in immune cell infiltration levels, and EPHB2 was markedly positively correlated with Th2 cell, NK cell, Eosinophils, Tgd, Mast cell, NK CD56bright cells and Tem while negatively correlated with Tcm and B cell in CC. Conclusion Our study shows that EPHB2 is a potential prognostic marker, and its overexpression is related to poor prognosis of CC, which is expected to be a new therapeutic target for CC.